[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367377-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367377-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","microrna-in-cancer-therapy-breakthroughsand-challenges-in-early-clinical-applications","MicroRNA in cancer therapy - breakthroughsand challenges in early clinical applications","","MicroRNAs (miRNAs) function as key regulators in cancer biology, shaping tumorigenesis, progression, and resistance to therapy. By modulating multiple oncogenic and tumor-suppressive pathways, they represent attractive therapeutic tools or targets. This review covers miRNA dysregulation across solid and hematological malignancies and discusses replacement and inhibition strategies, including delivery systems such as lipid nanoparticles and exosomes. It summarizes ongoing clinical trial progress while highlighting off-target effects, immune activation, and delivery inefficiencies, emphasizing optimized specificity and reduced toxicity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/microrna-in-cancer-therapy-breakthroughsand-challenges-in-early-clinical-applications/367377/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/microrna-in-cancer-therapy-breakthroughsand-challenges-in-early-clinical-applications/367377.png","ImageObject",300,407,{"name":42,"@type":43},"Jacob","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role do microRNAs play in cancer therapy?","Question",{"text":63,"@type":64},"MicroRNAs regulate tumorigenesis, progression, and resistance by modulating oncogenic and tumor-suppressive pathways. They can be used as therapeutic targets or tools to restore or inhibit dysregulated signaling.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do miRNA replacement and inhibition strategies work?",{"text":68,"@type":64},"Replacement strategies use miRNA mimics to restore downregulated tumor-suppressive miRNAs, while inhibition strategies use miRNA inhibitors (antimiRs) to neutralize overexpressed oncomiRs.",{"name":70,"@type":61,"acceptedAnswer":71},"What delivery systems are discussed for early clinical applications?",{"text":72,"@type":64},"The review highlights innovative delivery systems such as lipid nanoparticles and exosomes to package miRNAs and aim for tumor-cell targeted delivery.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367377,1790535927,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Di Martino et al. Journal of Experimental & Clinical Cancer Research (2025) 44:126 [https://doi.org/10.1186/s13046-025-03391-x](https://doi.org/10.1186/s13046-025-03391-x)  \nJournal of Experimental & Clinical Cancer Research  \nREVIEW Open Access  \nMicroRNA in cancer therapy: breakthroughsand challenges in early clinical applications  \nMaria Teresa Di Martino 1*, Pierosandro Tagliaferri1* and Pierfrancesco Tassone1*  \nAbstract  \nMicroRNAs (miRNAs) have emerged as pivotal regulators in cancer biology, influencing tumorigenesis, progression, and resistance to therapy. Their ability to modulate multiple oncogenic and tumor-suppressive pathways positions them as promising therapeutic tools or targets. This review examines the dual role of miRNAs in solid and hematological malignancies, starting from their dysregulation in various cancer types. Therapeutic approaches, including miRNA replacement and inhibition strategies, are discussed alongside innovative delivery systems such as lipid nanoparticles and exosomes. Despite their transformative potential, challenges persist, including off-target effects, immune activation, and delivery inefficiencies. Recent clinical trials demonstrate both progress and hurdles, underscoring the need for advanced strategies to optimize specificity and minimize toxicity. This review providesan updated comprehensive overview of the current landscape of miRNA-based therapies under early clinical investigation and explores future directions for integrating these approaches into precision oncology.  \nKeywords microRNA, miRNA, miRNA inhibitor, Non-coding RNA, ncRNA, Phase 1, miRNA therapeutics, First-inhuman, Early clinical trials, Clinical trials, Locked nucleic acid, LNA  \nIntroduction  \nCancer continues to pose a major global health challenge, with nearly 19 million new diagnoses and around 10 million fatalities annually [1, 2]. Despite notable progress in targeted therapies and immunotherapies, which have significantly improved survival in several patients, their impact is constrained by challenges such as treatment resistance and disease recurrence or progression. These events limit the chance of disease control by currently available therapeutics, emphasizing the need of  \n*Correspondence: Maria Teresa Di Martino [teresadm@unicz.it](teresadm@unicz.it)[ ](teresadm@unicz.it)Pierosandro Tagliaferri [tagliaferri@unicz.it](tagliaferri@unicz.it)[ ](tagliaferri@unicz.it)Pierfrancesco Tassone[tassone@unicz.it](tassone@unicz.it)  \n1Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy  \ninnovative, personalized strategies. While targeted therapies and immunotherapies offer enhanced precision by focusing on specific molecular targets or leveraging the immune system, unfortunately, their success is not universal. This is largely due to cancer’s complexity and heterogeneity, which result in differential sensitivity among patients, as well as high costs and logistic hurdles associated with these treatments, making widespread accessibility difficult.  \nRNA-based therapies, particularly those involving noncoding RNAs (ncRNAs), like microRNAs (miRNAs), represent a new emerging frontier, a promising alternative to address these challenges [3]. MiRNAs are the most studied class of regulatory ncRNAs of approximately 20–24 nucleotides, which regulate gene expression by binding to complementary sequences on messenger RNAs (mRNAs), leading to mRNA degradation or translation inhibition. Through this post-transcriptional regulation, miRNAs influence critical biological processes, such as  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other th","cbCaicH1v9w0UjSJ","https://ap.wps.com/l/cbCaicH1v9w0UjSJ","pdf",2826679,14,"English","# Abstract\n## Introduction\n## MiRNA-based therapies and delivery approaches\n## Challenges and early clinical trial perspectives","[{\"question\":\"What role do microRNAs play in cancer therapy?\",\"answer\":\"MicroRNAs regulate tumorigenesis, progression, and resistance by modulating oncogenic and tumor-suppressive pathways. They can be used as therapeutic targets or tools to restore or inhibit dysregulated signaling.\"},{\"question\":\"How do miRNA replacement and inhibition strategies work?\",\"answer\":\"Replacement strategies use miRNA mimics to restore downregulated tumor-suppressive miRNAs, while inhibition strategies use miRNA inhibitors (antimiRs) to neutralize overexpressed oncomiRs.\"},{\"question\":\"What delivery systems are discussed for early clinical applications?\",\"answer\":\"The review highlights innovative delivery systems such as lipid nanoparticles and exosomes to package miRNAs and aim for tumor-cell targeted delivery.\"}]","MicroRNA in cancer therapy - breakthroughsand challenges in early clinical applications | PDF",1790170528,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eac6059e345dfaac430c12381103f060.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bfce6f1a350cae25dc39ed9dffd3d69.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99889ea5b0314555420d4622ab4d3554.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1cd7d85f0000bc3c2d6143004461acef.webp",980,1306]